The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Yonesaka, Kimio, Kudo, Keita, Nishida, Satomi, Takahama, Takayuki, Iwasa, Tsutomu, Yoshida, Takeshi, Tanaka, Kaoru, Takeda, Masayuki, Kaneda, Hiroyasu, Okamoto, Isamu, Nishio, Kazuto, Nakagawa, Kazuhiko
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741788/
https://ncbi.nlm.nih.gov/pubmed/26418897
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items